Clinical Trial

Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) Therapy Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in the Treatment of Post-Traumatic Stress Disorder

Completed
View on ClinicalTrials.gov →
Summary
This randomized controlled trial aims to compare the efficacy of Eye Movement Desensitization and Reprocessing (EMDR) therapy versus Selective Serotonin Reuptake Inhibitors (SSRIs) in the treatment of Post-Traumatic Stress Disorder (PTSD). Adult patients diagnosed with PTSD will be randomly assigned to receive either EMDR therapy or SSRIs for a period of six weeks. The primary outcome is the rate of remission as measured by validated PTSD symptom severity scales at Week 6. Secondary outcomes include changes in functional impairment and patient-reported quality of life. The study seeks to determine whether EMDR therapy is a non-pharmacological alternative to SSRIs for achieving symptom remission in PTSD.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-25; most recent amendment 2026-05-03.
Status change: Active, Not Recruiting → Completed 2026-05-03
Status change: Recruiting → Active, Not Recruiting 2025-07-04
Status change: Not Yet Recruiting → Recruiting 2025-05-05
Trial Details
NCT Number NCT06955845
Lead Sponsor Asad Ullah Jan
Conditions PTSD, PTSD - Post Traumatic Stress Disorder
Enrollment 60 participants
Start Date 2025-05-06
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07